Introduction
============

Widespread antibiotic use has accelerated the incidence of antibiotic resistance (ABR). Although the exact magnitude of this global problem and its effect on human health are largely unknown, ABR against common bacterial pathogens has reached concerning levels in many parts of the world. As a result, many available treatment options are becoming ineffective.[@b1-idr-11-637] This situation was summarized by the World Health Day 2011 slogan "Combat antibiotic resistance: no action today, no cure tomorrow". ABR is complex and driven by many interrelated factors, including knowledge, attitudes, perceptions, expectations, time constraints, economic incentives, cultural factors, health system characteristics, and regulations.[@b2-idr-11-637]--[@b6-idr-11-637] A recognized key driver is the use, misuse, or overuse of antibiotics and unregulated consumer access to antibiotics.[@b7-idr-11-637],[@b8-idr-11-637] Although antibiotic overuse plays a pivotal role, underuse through inadequate dosing and poor adherence also plays an important role in ABR.[@b3-idr-11-637] In this regard, a complex association between outpatient antibiotic consumption and ABR has been observed in Europe.[@b9-idr-11-637],[@b10-idr-11-637] In addition, a strong link has been reported to exist between inpatient antibiotic consumption and the rate of ABR.[@b9-idr-11-637]

*Pseudomonas aeruginosa* is one of the most important nosocomial pathogens.[@b11-idr-11-637] The emergence of multidrug-resistant (MDR) *P. aeruginosa* strains that are resistant to all the known classes of antimicrobials, except for one or two, is becoming a major public health concern.[@b12-idr-11-637] Unfortunately, new drugs are not being manufactured at a pace that comes anywhere close to the rate at which microbes are gaining resistance to the existing drugs. Several studies have shown that better hand hygiene, isolation of infected patients, environmental disinfection, and targeted surveillance can improve the success rate of controlling MDR *Acinetobacter baumannii* infection;[@b13-idr-11-637]--[@b15-idr-11-637] however, there is no report on *P. aeruginosa* yet.

Although curbing the development of resistance in *P. aeruginosa* is important in hospitals, there are limited reports on MDR *P. aeruginosa* control measures in China. Antimicrobial stewardship (AMS) and infection control programs (ICPs) are coordinated strategies that are designed to promote and increase the appropriate use of antimicrobials, and they are important for conserving the effectiveness of antibiotics. In our study, we estimated the effects of AMS and ICPs on the resistance of *P. aeruginosa*, especially MDR *P. aeruginosa*, in a tertiary hospital center. To evaluate the efficacy of the infection control measures, the incidence of extensively drug-resistant (XDR) and MDR *P. aeruginosa*, the use of alcohol-based hand gel (ABHG), and the consumption of antibiotics during the study period were investigated.

Methods
=======

The Fourth Affiliated Hospital of Harbin Medical University, a 2,600-bed teaching hospital located in Harbin, China, has a 30-bed medical intensive care unit (ICU), a 20-bed surgical ICU, and a 15-bed cardiac care unit (CCU). Due to an obvious increase in the incidence of ABR *P. aeruginosa* infections since 2013, different ICPs have been launched sequentially at this hospital. In this study, we retrospectively evaluate the efficacy of the intervention measures that were in effect between January 2012 and December 2017.

Bacterial isolates
------------------

Between January 2012 and December 2017, clinical isolates were obtained from emergency rooms, medical and surgical wards, clinics, and ICUs at the Fourth Affiliated Hospital of Harbin Medical University. Clinical isolates from blood; respiratory, urinary, and wound infections; and other sources (pleural effusion, bile, and so on) were obtained for every year. Isolate identification was executed at the reference site as required (ie, antimicrobial susceptibility patterns did not fit the reported identification). Isolates were transferred to Amies semisolid transport media, shipped to the coordinating laboratory, subcultured on suitable media, and reserved in skim milk at −80°C until the minimum inhibitory concentration (MIC) was determined.

Antimicrobial sensitivity and resistance
----------------------------------------

The in vitro activity of regularly utilized antipseudomonal antimicrobials was determined by broth microdilution in line with the guidelines of the Clinical and Laboratory Standards Institute (CLSI).[@b16-idr-11-637],[@b17-idr-11-637] The antimicrobial activity of the antibiotics was determined using 96-well broth microdilution panels that were prepared in house. Colistin was examined in line with the recommendations of the CLSI--European Committee on Antimicrobial Susceptibility Testing (EUCAST).[@b18-idr-11-637] Polysorbate-80 was not added to the panels that were used to determine the MIC of colistin. The interpretive standards for MIC of the antibiotics were determined based on the CLSI breakpoints.[@b17-idr-11-637] MDR *P. aeruginosa* was defined as isolates that were not sensitive to at least one antibiotic from three or more different classes. XDR *P. aeruginosa* was defined as a subset of MDR *P. aeruginosa* isolates that were not sensitive to at least one antibiotic from five different classes. The XDR subset contained the total MDR isolates. For the purpose of our study, the five antibiotic classes included were aminoglycosides (gentamicin and amikacin), fluoroquinolones (ciprofloxacin), antipseudomonal cephalosporins (ceftazidime and cefoperazone/sulbactam), antipseudomonal penicillins (piperacillin/tazobactam), and carbapenems (meropenem and imipenem). Colistin and tigecycline were not utilized for the identification of MDR or XDR *P. aeruginosa*.

Infection control measures
--------------------------

A comprehensive and multifaceted six-point ICP was instituted in January 2013: Instructions for fundamental hygiene (ie, hand washing and suitable use of gloves) were provided via an education plan. To sustain and promote fundamental hygiene, dispensers for ABHG were fixed in every room and aisle in 2013.Instructions for contact with and seclusion of patients infected with MDR *P. aeruginosa* were provided, including placing patients in single rooms or in open-structured wards. These practices were enforced daily by infection control experts. Precautions for contact with infected patients were taken during the entire hospitalization period and enforced for every diagnostic or therapeutic course. A list of infected patients for seclusion and cautionary contact was also created. Moreover, these precautions were taken in patients admitted to the hospital again with a history of MDR *P. aeruginosa* infection. This program was enforced until colonization was removed.Positive monitoring was performed via weekly rectal, perineal, and pharyngeal swabs and/or tracheal bronchus aspirate in all the patients who were admitted to the ICU for \>2 days during times of ongoing transmission. Positive monitoring was strictly executed, especially in the ICU.Cultures from the hands of the medical staffs who had cared for the infected patients and the environment were analyzed at three time points during their ICU stay to investigate cross-infection and spread of infection to the staff.A rigid environmental cleaning plan for wards and for any equipment that infected patients might have touched was executed according to the suggestions of the Centers for Disease Control and Prevention.[@b19-idr-11-637] Some equipment (eg, stethoscopes) was used only for the source patient whenever possible and was kept within the confines of the ward.Periodical conferences were held with the health care workers of the infected areas every 2--4 weeks by the infection control group and were compulsory for the ICU workers. Moreover, all health care workers were regularly notified about the development of infection rates as part of the educational plan (monthly in the ICU and CCU and quarterly in the other wards).

Antibiotic stewardship
----------------------

From 2013 to 2017, antibiotic use was strictly restricted through AMS, which included the following classification management system for antibiotic use: Unrestricted use of antimicrobial agents: this is applicable in the case of antibacterial drugs that have been proven to be safe, effective, and inexpensive in clinical practice for a long time and have little influence on bacterial resistance. The doctor is granted unrestricted use of the antimicrobial drug and can prescribe them after examination.Restricted use of antimicrobial agents: there are limitations based on the efficacy, safety, cost, and so on, of the drug, in the case of antibiotics that have an obvious influence on bacterial resistance. Therefore, their use should be controlled. Doctors with an intermediate-level or above intermediate-level qualification are granted restricted use of the antimicrobial drug and can prescribe them after training and examination.Special use of antimicrobial agents: this is applicable in the case of antibiotics for which the adverse effects are obvious. In such cases, the agents should be prescribed with caution to prevent the bacteria from becoming too resistant and producing severe consequences. Limited clinical data are available on the efficacy or safety of new antibiotics or their superiority to those currently in use. Furthermore, these drugs are expensive and their use must therefore be strictly controlled. Doctors qualified at the sub-senior or above sub-senior level are granted special use of such antimicrobial drugs and can prescribe them after training and examination.

Data collection and analysis
----------------------------

The data of all patients in whom *P. aeruginosa* infection was confirmed were reviewed between 2012 and 2017. Isolates were defined as susceptible, resistant, or intermediate to an antibiotic for statistical analysis. Multiple positive isolates from one patient were considered as a single sample. ABHG use was calculated as the number of liters per 1,000 patient-days (PD) and utilized as a marker for compliance with hand hygiene rules. Antibiotic consumption was calculated as the defined daily dose (DDD) per 1,000 PD in line with the suggestions of the World Health Organization.[@b20-idr-11-637] Data on antibiotic consumption between January 2012 and December 2017 were obtained from the Hospital Pharmacy Service. The seven types of antibiotic agents tested in this study were β-lactam/β-lactamase inhibitor combinations (piperacillin/tazobactam and cefoperazon/sulbactam), extended-spectrum cephalosporins (ceftazidime), carbapenems (imipenem and meropenem), quinolones (ciprofloxacin), aminoglycosides (gentamicin and amikacin), glycopeptides (colistin), and tetracyclines (tigecycline). Consumption of all the antibiotics was calculated on the basis of the sum of values of the aforementioned broad-spectrum antibiotics.

The *χ*^2^ test was utilized to determine the rate of susceptibility and resistance to *P. aeruginosa* and ABHG consumption during the study period. Segmented regression analysis was performed to test obvious changes in the susceptibility and resistance of *P. aeruginosa*. Spearman's rank association was applied to confirm the correlation between ABHG use or antibiotic consumption and the rate of MDR *P. aeruginosa*. All examinations were two-tailed, and *P*\<0.05 was considered to indicate statistical significance. Analyses were performed using SPSS v. 17 (SPSS Inc., Chicago, IL, NY).

Results
=======

A total of 2,241 *P. aeruginosa* clinical isolates were collected between January 2012 and December 2017. The number of isolates obtained annually varied between 221 and 486. [Table 1](#t1-idr-11-637){ref-type="table"} presents data related to antibiotic susceptibility and resistance of the isolates. Colistin and tigecycline were the most effective antipseudomonal antibiotics assessed: 99.6 and 98.83% of the isolates showed in vitro susceptibility to colistin and tigecycline, respectively, and 0.4 and 1.17% showed resistance to colistin and tigecycline, respectively. In contrast, gentamicin and amikacin were the least effective antibiotics evaluated: only 68.4% of the isolates were susceptible and 29.01% were resistant to gentamicin and 76.07% were susceptible and 22.22% were resistant to amikacin. Colistin and tigecycline remained the most effective antipseudomonal antibiotics assessed, with 98.41 and 95.6% of the MDR *P. aeruginosa* isolates showing in vitro susceptibility to colistin and tigecycline, respectively. Furthermore, colistin and tigecycline were the most effective antipseudomonal antibiotics assessed, with 94 and 91% of the XDR *P. aeruginosa* isolates showing in vitro susceptibility to colistin and tigecycline, respectively.

The sensitivity of the isolates, stratified by study year, is presented in [Table 2](#t2-idr-11-637){ref-type="table"} and [Figure 1](#f1-idr-11-637){ref-type="fig"}. Over the 6-year study period, colistin and tigecycline were found to be stable and to have the highest susceptibility among the antipseudomonal antimicrobials. After the interventions were implemented in 2013, the susceptibility of the other antipseudomonal antimicrobials, except for piperacillin/tazobactam, obviously improved. Only susceptibility to piperacillin/tazobactam was found to be reduced.

Resistance to the isolates, stratified by study year, is presented in [Table 3](#t3-idr-11-637){ref-type="table"} and [Figure 2](#f2-idr-11-637){ref-type="fig"}. Colistin and tigecycline were found to be stable and to have the lowest resistance as antipseudomonal antimicrobials. The resistance to other antipseudomonal antimicrobials clearly decreased after the interventions were implemented in 2013.

Overall, 18.5% of the *P. aeruginosa* isolates assessed were MDR and 3.5% of the *P. aeruginosa* isolates assessed were XDR. As shown in [Table 2](#t2-idr-11-637){ref-type="table"} and [Figure 3](#f3-idr-11-637){ref-type="fig"}, the percentage of MDR isolates ranged between 15 and 22 across the study years. AMS and ICPs were strictly implemented in 2013. The incidence rate of MDR *P. aeruginosa* decreased from 22 to 15%, and a statistically significant decline was observed in the MDR *P. aeruginosa* isolates over time (*P*=0.04). Segmented regression analysis showed a significant change in the trend of incidence rate (*r*=−0.018, *P*=0.032). The incidence rate of XDR *P. aeruginosa* decreased from 5.8 to 1%, and an obvious reduction trend was observed in the XDR isolates over time ([Table 2](#t2-idr-11-637){ref-type="table"} and [Figure 4](#f4-idr-11-637){ref-type="fig"}).

ABHG use increased gradually from 2013 to 2017 ([Table 4](#t4-idr-11-637){ref-type="table"}), and the consumption per 1000 PD was as follows: 0.6 L in 2012, 3.8 L in 2013, 5.7 L in 2014, 8.5 L in 2015, 9.8 L in 2016, and 10.9 L in 2017 (*P*=0.005). ABHG use was not significantly correlated to the incidence rate of MDR *P. aeruginosa* (*r*=0.14; *P*=0.3).

The consumption pattern of antimicrobials is shown in [Figure 5](#f5-idr-11-637){ref-type="fig"} and [Table 4](#t4-idr-11-637){ref-type="table"}. AMS and ICPs were strictly implemented from 2013 to 2017. The DDD per 1000 PD of total antibiotics decreased gradually from 44.19 to 38.15, and the reduction was significant (*P*=0.04). Furthermore, antibiotic usage was significantly correlated to the incidence rate of MDR *P. aeruginosa* (*r*=0.63, *P*=0.025).

Discussion
==========

The increasing incidence of MDR *P. aeruginosa* is a consequence of the ability of this microorganism to develop resistance to almost all antimicrobial agents during antimicrobial chemotherapy, either by chromosomal gene mutation selection or by horizontal gene transfer.[@b21-idr-11-637],[@b22-idr-11-637] The escalating situation of MDR *P. aeruginosa* should be addressed promptly, and the medical profession should undertake most responsibilities, to save one of the antibiotic's most precious and long-term resources.[@b23-idr-11-637] Cutting down on the unreasonable usage of antibiotics has been shown to improve patient prognosis and contain the adverse effects of antimicrobial usage (including antimicrobial resistance, side effects of antibiotics, and medical costs).[@b24-idr-11-637] Although this is not a simple task especially given the associated cultural factors,[@b25-idr-11-637],[@b26-idr-11-637] strategic interventions for behavior change to promote prudent antibiotic use and prescription are urgently required and attainable, as demonstrated in many European countries.[@b25-idr-11-637],[@b27-idr-11-637] Simple solutions that consider local cultures and that can be scaled up to become self-sustainable should be proposed.[@b28-idr-11-637] However, changing antibiotic prescription behavior is a complex initiative that requires multifaceted interventions.[@b29-idr-11-637]

AMS is one the measures that was planned to impel and enhance the reasonable usage of antibiotics and is important for ensuring the continued effectiveness of antimicrobials. Australia's first National Antimicrobial Resistance policy for 2015--2019 mentions the demand for resources to sustain the implementation of AMS for all hospitals.[@b30-idr-11-637] In particular, it is important for medical workers to make patients aware that they are twice as likely to carry resistant bacteria after antimicrobial use as someone who has not used the antimicrobial before.[@b31-idr-11-637]--[@b33-idr-11-637] One study showed that providing education about ICPs, hand hygiene, and the judicious use of carbapenems may decrease the nosocomial incidence of carbapenem-resistant *A. baumannii*.[@b34-idr-11-637] Another study showed that apart from infection control measures, the removal of key antibiotic selection pressures during a national antibiotic stewardship intervention can result in large and sustained reduction in hospital-associated and community-associated methicillin-resistant *Staphylococcus aureus* infection.[@b35-idr-11-637] Improved monitoring of hospital-acquired infections and effective infection control measures may be the best way to solve the present problem.[@b36-idr-11-637]

In our study, 2,241 *P. aeruginosa* clinical isolates were collected between January 2012 and December 2017. AMS and ICPs were strictly implemented in 2013, and the incidence rate of MDR *P. aeruginosa* decreased from 22 to 15%. A statistically obvious reduction in MDR *P. aeruginosa* isolates was found over time. The incidence rate of XDR *P. aeruginosa* decreased from 5.8 to 1%, and an obvious reduction was found in the number of XDR isolates. ABHG use was not significantly related to the incidence of MDR *P. aeruginosa*, whereas antibiotic consumption was significantly related to the incidence of MDR *P. aeruginosa*.

AMS and ICPs were strictly implemented from 2013 to 2017. The DDD per 1,000 PD of total antibiotics decreased gradually from 44.19 to 38.15, and the reduction was statistically significant. The DDD is \~23/1,000 population/day in Australia and 11/1,000 population/day in the Netherlands.[@b37-idr-11-637],[@b38-idr-11-637] Clearly, our values are higher than those reported in Australia and the Netherlands. This may be related to the insufficient of administration of antibiotic application.

A hospital center study in Southwest China reported that piperacillin/tazobactam was the most effective antibiotic against *P. aeruginosa* isolates and that antibiotic use prior to admission was an independent risk factor for *P. aeruginosa* infection.[@b39-idr-11-637] In our study, however, colistin and tigecycline were found to be the most effective antipseudomonal antibiotics assessed. Gentamicin and amikacin were the least effective antibiotics evaluated, and susceptibility to only piperacillin/tazobactam was found to be deteriorated. The differences in the reports of these two hospitals in the same country could be explained by differences in the habit, frequency, and region of antibiotic use.

Widespread transmissible colistin resistance is a major concern in the current era of MDR gram-negative infections because colistin is commonly used to treat infections caused by these organisms, despite its nephrotoxicity and limitations in determining susceptibility and appropriate dosing regimens.[@b40-idr-11-637],[@b41-idr-11-637] In spite of the above shortcomings of the two drugs, in our study, however, colistin and tigecycline were the most effective antipseudomonal antibiotics assessed.

Our study findings indicated that the trends in the resistance of *P. aeruginosa* to antimicrobial agents were influenced by the antibiotic stewardship and ICPs implemented at the Chinese university hospital and that antibiotic usage was significantly related to the incidence rate of MDR *P. aeruginosa*. Currently, new antimicrobials with resistance to *P. aeruginosa* are not being developed at a fast enough pace. Therefore, controlling the resistance of *P. aeruginosa* by combining antibiotic stewardship and ICPs is necessary. The monitoring of *P. aeruginosa*, AMS, and comprehensive ICPs may be one of the best and most effective ways to solve the developing resistance of *P. aeruginosa*.

Conclusion
==========

Our study showed that the concomitant implementation of strict AMS and comprehensive ICPs could effectively control the resistance of *P. aeruginosa* at the current tertiary hospital center over a 6-year period. The yearly consumption of antimicrobial agents with AMS significantly decreased, and the use of ABHG significantly increased over the study period. Furthermore, the incidence rates of MDR and XDR *P. aeruginosa* showed a sustained decrease from 2013 to 2017. Among the common antipseudomonal antimicrobials examined, colistin and tigecycline were found to be the most stable in terms of the susceptibility and resistance of the isolates, while the other antipseudomonal antimicrobials showed significant fluctuation and improvement after 2014. A statistically obvious correlation was found between the incidence rate of MDR *P. aeruginosa* and the consumption of antimicrobial agents. However, endemic MDR *P. aeruginosa* was effectively controlled with strict AMS and comprehensive ICPs, including hospital staff education, active surveillance of cultures, limited contact with and isolation of patients, environmental cleaning, hand hygiene promotion, and a classification management system for antibiotic use, among others. Without the application of these interventions simultaneously, successful control of the resistance of MDR *P. aeruginosa* would have been difficult. Thus, the monitoring of *P. aeruginosa*, AMS and comprehensive ICPs may be one of the best and effective ways to resolve the problem of resistance of *P. aeruginosa* at the current tertiary hospital center.
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###### 

Antimicrobial susceptibility of *P. aeruginosa* clinical isolates obtained from patients at a hospital center in China, 2012--2017

  Antimicrobial             All isolates (n=2,241)   MDR (n=414)   XDR (n=78)                                           
  ------------------------- ------------------------ ------------- ------------ ------- ------- ------- ------- ------- ------
  Amikacin                  4                        16            ≤1           \>64    76.07   1.71    22.22   56      24.5
  Ceftazidime               4                        32            ≤0.25        \>32    74.82   7.7     17.48   20.4    0
  Ciprofloxacin             0.25                     4             ≤0.06        \>16    73      10.1    16.9    23      0
  Colistin                  1                        2             ≤0.06        \>16    99.6    0       0.4     98.41   95.6
  Gentamicin                2                        8             ≤0.5         \>32    68.4    2.59    29.01   45.1    1.3
  Meropenem                 0.5                      8             ≤0.03        \>32    76.55   6.2     17.25   71      67
  Piperacillin/tazobactam   4                        64            ≤1           \>128   81.07   5.11    13.82   22.3    0
  Cefoperazone/sulbactam    4                        64            ≤1           \>128   76.4    17.49   6.11    70.35   69
  Imipenem                  0.5                      8             ≤0.03        \>32    71.23   8.85    19.92   60      65
  Tigecycline               1                        2             ≤0.06        \>16    98.83   0       1.17    94      91

**Notes:**

\%*S* = %susceptible, %*I* = %intermediate, %*R* = %resistant; breakpoint interpretation: amikacin *S*≤16 μg/mL, *I*=32 μg/mL, *R*≥64 μg/mL; ceftazidime *S*≤8 μg/mL, *I*=16 μg/mL, *R*≥32 μg/mL; ciprofloxacin *S*≤1 μg/mL, *I*=2 μg/mL, *R*≥4 μg/L; colistin *S*≤2 μg/mL, *I*=4 μg/mL, *R*≥8 μg/mL; gentamicin *S*≤4 μg/mL, *I*=8 μg/mL, *R*≥16 μg/mL; meropenem *S*≤2 μg/mL, *I*=4 μg/mL, *R*≥8 μg/mL; piperacillin/tazobactam *S*≤16/4 μg/mL, *I*=32/4 μg/mL, *R*≥128/4 μg/mL; cefoperazone/sulbactam *S*≤16/4 μg/mL, *I*=32/4 μg/mL, *R*≥128/4 μg/mL; imipenem *S*≤2 μg/L, *I*=4 μg/mL, *R*≥8 μg/mL; tigecycline *S*≤2 μg/mL, *I*=4 μg/mL, *R*≥8 μg/mL.

**Abbreviations:** Max, maximum; MDR, multidrug resistant; Min, minimum; MIC, minimum inhibitory concentration; *P. aeruginosa*, *Pseudomonas aeruginosa*; XDR, extensively drug resistant.

###### 

Antimicrobial susceptibility of *P. aeruginosa* clinical isolates obtained from patients at a hospital center in China

  Antimicrobial             %Susceptible                                      *P*-value                               
  ------------------------- ------------------------------------------------- ----------- ------ ------ ------ ------ ---------
  Amikacin                  70.6                                              74          60     69     88.5   94.3   \<0.001
  Ceftazidime               71.5                                              75          73     66     78.5   84.9   \<0.001
  Ciprofloxacin             64.7                                              66          79     79     70     79.3   \<0.001
  Colistin                  97.6                                              100         100    100    100    100    NS
  Gentamicin                63.7                                              62          53     70     76     85.7   \<0.001
  Meropenem                 71.5                                              76          73     75     80     83.8   \<0.001
  Piperacillin/tazobactam   78.7                                              82          93     85     68     79.7   \<0.001
  Cefoperazone/sulbactam    70                                                82          76     75.6   75     79.8   \<0.001
  Imipenem                  81.7                                              84          57     45     79     80.7   \<0.001
  Tigecycline               100                                               100         99     98     98     98     NS
                            **% of isolates with the MDR or XDR phenotype**                                           
  MDR                       20                                                22          18.5   17     17.4   15     0.04
  XDR                       5.8                                               4.9         3.5    2.1    1.2    1      nd

**Note:** nd, statistical analysis not performed for the XDR subset due to the small number of isolates.

**Abbreviations:** MDR, multidrug resistant; nd, no data; NS, not significant; *P. aeruginosa*, *Pseudomonas aeruginosa*; XDR, extensively drug resistant.

###### 

Antimicrobial resistance of ***Pseudomonas aeruginosa*** clinical isolates obtained from patients at a hospital center in China

  Antimicrobial             %Resistance   *P*-value                              
  ------------------------- ------------- ----------- ----- ------ ------ ------ ---------
  Amikacin                  27.9          25          39    28     11.5   3.6    \<0.001
  Ceftazidime               22.5          17          23    28     10.5   8.6    \<0.001
  Ciprofloxacin             22.8          14          16    18     19     13.6   \<0.001
  Colistin                  2.4           0           0     0      0      0      NS
  Gentamicin                34.8          35          45    25     21.5   11.4   \<0.001
  Meropenem                 19.5          21          23    22     17     15.2   \<0.001
  Piperacillin/tazobactam   21.3          18          7     15     8.5    2.9    \<0.001
  Cefoperazone/sulbactam    7.6           5.8         8.2   11.4   7.5    6.5    \<0.001
  Imipenem                  12            14          28    30     15.5   17.1   \<0.001
  Tigecycline               0             0           1     2      2      2      NS

**Abbreviation:** NS, not significant.

###### 

Consumption of antimicrobial agents and ABHG during the study period at a hospital center in China

                                Year   *P*-value                                   
  ----------------------------- ------ ----------- ------- ------- ------- ------- -------
  DDD (g/1,000 patient-days)    45     44.19       43.37   39.52   38.55   38.15   0.04
  ABHG (L/1,000 patient-days)   0.6    3.8         5.7     8.5     9.8     10.9    0.005

**Abbreviations:** ABHG, alcohol-based hand gel; DDD, daily defined dose.
